ICH GCP stands for the International Council for Harmonisation’s Guideline for Good Clinical Practice. It is an international quality standard that governs how clinical trials involving human participants are designed, conducted, recorded, and reported. The guideline has two core goals: protecting the rights, safety, and well-being of trial participants, and ensuring the data produced by clinical trials is reliable. Regulatory agencies in the United States, European Union, Japan, and dozens of other countries recognize ICH GCP as the baseline standard for any clinical trial whose results will be submitted for drug or device approval.
Why ICH GCP Exists
Before ICH GCP, each country had its own set of rules for running clinical trials. A pharmaceutical company testing a new drug in multiple countries had to navigate different standards in each one, which created inconsistencies in how participants were protected and how data was collected. The ICH brought together regulators and industry representatives from the US, Europe, and Japan in the 1990s to create a single, unified guideline. The result was ICH E6, commonly called ICH GCP.
The guideline is rooted in the ethical principles of the Declaration of Helsinki, the foundational document on ethical medical research. But ICH GCP goes further than ethics alone. It also sets detailed, practical requirements for documentation, data handling, investigational product management, and oversight responsibilities. This dual focus on ethics and data quality is what makes it the backbone of modern clinical research worldwide.
The 13 Core Principles
ICH GCP is built on 13 fundamental principles. Some are ethical commitments, others are operational requirements. Together, they define what a properly run trial looks like:
- Ethical foundation. Trials must follow ethical principles consistent with the Declaration of Helsinki and applicable regulations.
- Risk-benefit balance. Foreseeable risks must be weighed against anticipated benefits before a trial begins, and the trial should only proceed if the benefits justify those risks.
- Participant priority. The rights, safety, and well-being of participants are the most important considerations and take precedence over the interests of science and society.
- Adequate supporting data. Enough preclinical and clinical information about the investigational product must exist to justify the proposed trial.
- Scientific soundness. Trials must be scientifically valid and described in a clear, detailed protocol.
- Ethics committee approval. The trial protocol must receive approval from an institutional review board (IRB) or independent ethics committee (IEC) before enrollment begins.
- Qualified medical oversight. Medical care and decisions for participants must be the responsibility of a qualified physician or dentist.
- Qualified personnel. Everyone involved in the trial must have the education, training, and experience needed for their specific role.
- Informed consent. Freely given informed consent must be obtained from every participant before any trial-related activity begins.
- Accurate record-keeping. Trial data must be recorded, handled, and stored in a way that allows accurate reporting, interpretation, and verification.
- Confidentiality. Records that could identify participants must be kept private in compliance with applicable regulations.
- Product standards. Investigational products must be manufactured, stored, and handled according to good manufacturing practice and used per the approved protocol.
- Quality systems. Procedures that assure the quality of every aspect of the trial must be in place.
What the Principal Investigator Must Do
The principal investigator (PI) is the physician or scientist who takes personal responsibility for the conduct of a clinical trial at a given site. ICH GCP assigns them a wide range of duties. They must be properly qualified and thoroughly familiar with the investigational product and its appropriate use. They are required to conduct the trial in compliance with the approved protocol and to ensure all trial-related medical decisions are made by a qualified physician.
The PI is also directly responsible for participant safety. This means providing adequate medical care for participants who experience side effects or adverse events, and immediately reporting all serious adverse events to the study sponsor with a written follow-up. They must ensure the investigational product is stored, tracked, and used exactly as specified. And critically, they are responsible for making sure every participant gives informed consent before any study activity begins.
How Informed Consent Works Under GCP
Informed consent is one of the most detailed sections of the guideline, reflecting how central it is to ethical research. ICH GCP requires 20 specific elements in the informed consent form. These fall into two broad categories.
The first category covers information that applies regardless of the study: that the trial involves research, that participation is voluntary and can be withdrawn at any time without penalty, what compensation is available if a trial-related injury occurs, how participant records will be kept confidential, who will have access to those records (monitors, auditors, ethics committees, regulators), and who to contact with questions.
The second category is study-specific: the purpose of the trial, what treatments or procedures are involved, which aspects are experimental, the foreseeable risks and possible benefits, what alternative treatments exist, the expected duration of participation, and the approximate number of participants in the trial. Participants must also be told about any circumstances under which their participation could be ended without their consent, and that they will be informed of any new findings that might affect their willingness to continue.
The consent form must be signed and dated by the participant (or a legally acceptable representative) and the person conducting the consent discussion before any trial procedures begin. The process must allow ample time for the participant to ask questions and consider the information. Consent is not simply a signature on a form. It requires genuine comprehension and voluntary agreement.
The Role of Ethics Committees
Every clinical trial governed by ICH GCP must be reviewed and approved by an IRB or IEC before it can begin. The purpose of this committee is to safeguard the rights, safety, and well-being of all trial participants, serving as an independent check on the research team.
ICH GCP recommends that an IRB/IEC have at least five members, including at least one person whose primary expertise is outside the medical sciences and at least one member who is independent of the institution or investigator site. This composition is designed to ensure the committee can evaluate both the scientific merit and the ethical dimensions of a study from diverse perspectives.
The committee reviews the protocol and any amendments, the informed consent materials, the Investigator’s Brochure (a document summarizing what’s known about the drug being tested), plans for participant compensation, recruitment advertisements, and ongoing safety information. Review doesn’t stop at approval. The IRB/IEC must conduct continuing review of each ongoing trial at intervals appropriate to the level of risk participants face.
Essential Documents and Record-Keeping
ICH GCP requires an extensive set of documents to be created and maintained throughout a trial’s lifecycle. These fall into three phases: before the trial starts, during the trial, and after it closes.
Before enrollment begins, the trial file must include the signed protocol, the Investigator’s Brochure, the approved informed consent form, IRB/IEC approval documentation, evidence of the investigator’s qualifications, agreements between the sponsor and the research site, laboratory certifications, the master randomization list, and shipping records for the investigational product, among others.
During the trial, updated versions of many of these documents are maintained, along with records of any protocol amendments, revised consent forms, continuing review approvals, and safety reports. The point of this extensive paper trail is verification. Regulators, auditors, and monitors need to be able to reconstruct what happened in a trial, confirm that participants were properly consented, and verify that the data in the final report matches what was actually collected at the site.
The E6(R3) Update
The original ICH GCP guideline was written in 1996. A second revision, E6(R2), added requirements around electronic records and risk-based monitoring in 2016. The most recent version, E6(R3), represents a more significant overhaul. The FDA describes it as a significant evolution in the global clinical trial landscape, aimed at modernizing GCP principles in alignment with current scientific and technological advances.
The R3 revision emphasizes “quality by design,” a concept that pushes research teams to build quality into the trial from the planning stage rather than relying on after-the-fact checks. It also reflects the growing use of decentralized trials, electronic consent, wearable devices, and real-world data sources that didn’t exist when the original guideline was written. The core ethical commitments remain unchanged. What has evolved is the practical framework for meeting those commitments in a research environment that looks very different from the 1990s.